AT501 / AbClon - LARVOL DELTA

App Clone succeeds in paying 19 billion won worth of CB and third-party allocation paid-in capital increase [Google translation] (AbClon Press Release) - "Antibody drug development specialist AbClon announced on the 13th that it has completed the payment of a total of KRW 19 billion in CB and third- party allocation paid-in capital increase issuance proceeds...The company explained that with this funding, it will be able to focus on its ongoing clinical trials and R&D while improving its financial soundness. In particular, it will focus on completing Phase 2 clinical trials for the successful commercialization of its core pipeline , CAR-T treatment AT101. It also aims to successfully develop follow-up pipelines, such as switchable CAR-T treatment AT-501 and dual antibody treatment AM105, to meet market and investor expectations ."

Financing • Hematological Malignancies • Solid Tumor

AbClon, CB·CPS issuance of 31 billion decided.. Daily Partners Lead [Google translation] (Biospectator) - "AbClon held a board meeting on the 28th and announced that it decided to raise 31 billion won through a paid-in capital increase by issuing convertible bonds (CB) and third-party allocated convertible preferred shares (CPS)...AppClon explained that this funding acquisition will allow it to focus on clinical trials and R&D while improving its financial soundness. In particular, it emphasized that it will focus on completing Phase 2 clinical trials for the successful commercialization of its core AT101 and meeting market and investor expectations through the successful development of its core pipeline....AppClon plans to use this fund to focus on completing and commercializing phase 2 clinical trials of its CD19 CAR-T 'AT101' for blood cancer and developing the next-generation solid cancer HER2 switchable CAR-T 'AT501'. It also plans to strategically use it to develop T cell engager EGFRx4-1BB dual antibodies 'AM105 (colon cancer)' and 'AT109 (prostate cancer)'."

Financing • Colon Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Prostate Cancer • Solid Tumor

AppClon, CAR-T Treatment AT101 Expected to Be Rapidly Approved… Anticancer Effect Even Against Mutations [Google translation] (Money Today) - "AT501, a switchable CAR-T pipeline, uses a switching molecule that can target two or more disease proteins. It is possible to change the target disease protein by replacing the already developed switching molecule, which can shorten the development time. The company plans to apply for an Investigational New Drug (IND) phase 1 clinical trial plan in the second half of next year."

IND • New P1 trial • Oncology • Solid Tumor

AppClon Acquires Chinese Patent for CAR-T Zipper Switch Technology “Possible to Develop New Drugs More Advanced Than Antibody Treatments” [Google translation] (Hankyung) - "AppClon announced on the 6th that it has obtained a Chinese patent for its zipper switch technology used in solid cancer chimeric antigen receptor T (CAR-T) cell therapy. The zipper switch technology patented this time utilized AppClon’s self-developed affibody. It can be applied to antibody-based treatments including CAR-T cell therapy and can control efficacy (On/Off)...The core technology of the existing AppClon switchable CAR-T (zCAR-T)-based treatment 'AT501' is a switch substance that combines cotinine and affibody....By utilizing this patent that expands the existing technology, binding between affibodies is possible, and through this, the production process for the switch substance is expected to be simplified and cost reduced."

Patent • Oncology • Solid Tumor

AbClone presents AT501∙ AM105 at the American Association for Cancer Research, “Presenting an innovative anticancer treatment approach” [Google translation] (AbClon Press Release) - "AbClon announced on the 11th that it participated in the American Association for Cancer Research (AACR) from the 5th to the 10th...and presented the latest research results on AT501 and AM105, new anticancer drug candidates...AbClone has designed the HER2 switch, which tracks only cancer proteins in solid tumors. It was confirmed in animal models that strong anticancer activity was maintained when administered together with switch CAR-T treatment. This is an innovative approach that is completely different from existing CAR-T treatments, and it is said that even in reactive or recurrent models, cancer can be completely suppressed by boosting the drug's efficacy again with just an additional switch....In addition, AM105 expanded the CD137 binding site to four and showed excellent efficacy in recruiting immune cells and activating T cells. It is expected to be easy to commercialize as it has characteristics that do not impede productivity and stability."

Preclinical • Oncology • Solid Tumor

AbClon discloses research results on anticancer new drug candidates AT501 and AM105 at the American Association for Cancer Research [Google translation] (AbClon Press Release) - "AbClon, a company specializing in CAR-T (chimeric antigen receptor -T) treatments , announced on the 4th that it will present research results on anticancer new drug candidates at the American Association for Cancer Research (AACR 2024) to be held in San Diego, USA in April...AbClon announces the research results of 'AT501', which introduces solid tumor CAR-T treatment technology based on a switchable platform, and 'AM105', which introduces AffiMab dual antibody technology. The presentation of AT501 will be presented by co-researcher Professor Jeong Jun-ho...AM105 effectively induced 4-1BB aggregation, and excellent efficacy was also confirmed in a stress model evaluation reflecting the low number of T cells in the solid tumor tumor microenvironment. At AACR 2024, we plan to announce the characteristics of AM105 and the results of research on its anticancer efficacy....'At AACR 2024, we plan to announce the research results of AT501 and AM105...'"

Preclinical • Oncology • Solid Tumor

AbClon registers CAR-T tech patent in US, Canada (Korea Biomedical Review) - "AbClon, a Kosdaq-listed biotech firm, said it registered its technology patent related to chimeric antigen receptor (CAR)-T cell therapy in the U.S. and Canada, respectively. In the U.S., AbClon registered the patent on its switchable CAR-T platform technology, applicable in AT501 for ovarian cancer. In Canada, the registered patent involves CAR-T therapy technology using the h1218 antibody of AT101, the company’s key pipeline, for blood cancer....The company aims to strengthen intellectual property on AT101 worldwide by registering patents in more countries."

Patent • Gynecologic Cancers • Hematological Malignancies • Oncology • Ovarian Cancer • Solid Tumor

AbClone, G+ Life Science and Joint Development of Car-T Cell Therapy [Google translation] (BioTimes) - "AbClon...is working on joint development of an allogeneic CAR-T cell therapy product with Gplus Life Science...AbClon signed a joint research business agreement with Gplus Life Sciences, and expanded its R&D area beyond autologous CAR-T technology to a similarly-derived technology."

Licensing / partnership • Hematological Malignancies • Oncology • Ovarian Cancer

Korean drugmakers aim to export technology during US cancer convention (Korea Biomedical Review) - "Despite the protracted Covid-19 pandemic, many Korean biopharmaceutical companies plan to participate in the 2021 American Association for Cancer Research (AACR)...Abclone will present the CAR-T cell therapy research results AT101 (blood cancer treatment) and AT501 (ovarian cancer treatment)...Aptabio will present the phase 1 clinical trial design for SJP1604 in treating patients with acute myeloid leukemia (AML), which is under joint research with Samjin Pharmaceutical...PharmAbcine plans to announce the preclinical results of PMC-309, an immune anticancer candidate."

P1 data • Preclinical • Acute Myelogenous Leukemia • Gynecologic Cancers • Hematological Malignancies • Leukemia • Oncology • Ovarian Cancer

Abclone announces CAR-T research achievements at European CAR-TCR conference (docdocdoc.co.kr) - "AbClone participated in the 'CAR-TCR Europe Summit' held from the 16th to the 18th to demonstrate the results of non-clinical research on its chimeric antibody receptor (CAR)-T blood cancer treatment 'AT101' and ovarian cancer treatment 'AT501'...'ApClon’s CAR-T cell therapy pipeline will be an opportunity to objectively prove the excellence of AT101’s domestic clinical trial plan (IND), which is expected at the end of May.'"

IND • Preclinical • Gynecologic Cancers • Oncology • Ovarian Cancer

AbClon expands CAR-T pipeline to treat solid tumor (Korea Biomedical Review) - "AbClon said the company is expanding its CAR-T (chimeric antigen receptor-T) pipelines targeting mesothelin and CD30. CAR T-cell therapy is a form of immunotherapy using specially altered T cells to fight cancer...AT191...targeting disease protein CD19, and AT501, an ovarian cancer therapy targeting HER2. It also has made considerable progress in research and development related to solid tumor CAR-T by, for instance, developing Affibody targeting mesothelin."

Clinical • Gastrointestinal Cancer • Gynecologic Cancers • Hematological Malignancies • Hodgkin Lymphoma • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor